Back to Search Start Over

Multigenic lentiviral vectors for combined and tissue-specific expression of miRNA- and protein-based antiangiogenic factors

Authors :
T G Jensen
Anne Kruse Hollensen
Lars Aagaard
Anne Louise Askou
Jacob Giehm Mikkelsen
Yvan Arsenijevic
Toke Bek
Corinne Kostic
Thomas J. Corydon
Source :
Askou, A L, Aagaard, L, Kostic, C, Arsenijevic, Y, Hollensen, A K, Bek, T, Jensen, T G, Mikkelsen, J G & Corydon, T J 2015, ' Multigenic lentiviral vectors for combined and tissue-specific expression of miRNA-and protein-based antiangiogenic factors ', Molecular therapy. Methods & clinical development, vol. 2, pp. 14064 . https://doi.org/10.1038/mtm.2014.64, Molecular Therapy: Methods & Clinical Development, Vol 2, Iss, Pp-(2015), Molecular Therapy. Methods and Clinical Development, vol. 2, pp. 14064, Molecular Therapy. Methods & Clinical Development
Publication Year :
2015

Abstract

Lentivirus-based gene delivery vectors carrying multiple gene cassettes are powerful tools in gene transfer studies and gene therapy, allowing coexpression of multiple therapeutic factors and, if desired, fluorescent reporters. Current strategies to express transgenes and microRNA (miRNA) clusters from a single vector have certain limitations that affect transgene expression levels and/or vector titers. In this study, we describe a novel vector design that facilitates combined expression of therapeutic RNA- and protein-based antiangiogenic factors as well as a fluorescent reporter from back-to-back RNApolII-driven expression cassettes. This configuration allows effective production of intron-embedded miRNAs that are released upon transduction of target cells. Exploiting such multigenic lentiviral vectors, we demonstrate robust miRNA-directed downregulation of vascular endothelial growth factor (VEGF) expression, leading to reduced angiogenesis, and parallel impairment of angiogenic pathways by codelivering the gene encoding pigment epithelium-derived factor (PEDF). Notably, subretinal injections of lentiviral vectors reveal efficient retinal pigment epithelium-specific gene expression driven by the VMD2 promoter, verifying that multigenic lentiviral vectors can be produced with high titers sufficient for in vivo applications. Altogether, our results suggest the potential applicability of combined miRNA- and protein-encoding lentiviral vectors in antiangiogenic gene therapy, including new combination therapies for amelioration of age-related macular degeneration.

Details

Language :
English
Database :
OpenAIRE
Journal :
Askou, A L, Aagaard, L, Kostic, C, Arsenijevic, Y, Hollensen, A K, Bek, T, Jensen, T G, Mikkelsen, J G & Corydon, T J 2015, ' Multigenic lentiviral vectors for combined and tissue-specific expression of miRNA-and protein-based antiangiogenic factors ', Molecular therapy. Methods & clinical development, vol. 2, pp. 14064 . https://doi.org/10.1038/mtm.2014.64, Molecular Therapy: Methods & Clinical Development, Vol 2, Iss, Pp-(2015), Molecular Therapy. Methods and Clinical Development, vol. 2, pp. 14064, Molecular Therapy. Methods & Clinical Development
Accession number :
edsair.doi.dedup.....a30ee5f92e014eec1da3f57cc3c44c27
Full Text :
https://doi.org/10.1038/mtm.2014.64